Evaluation of next generation sequencing (NGS) as a rapid, alternative assay for in vivo and in vitro adventitious virus testing for vaccine safety

This project proposes to: 1) compare NGS with currently used in vivo animal assay and in vitro cell culture and PCR assays; and 2) develop a well-qualified reference virus database (RVDB II)

Project status

100% Completed

Industry Need

Next generation sequencing (NGS) is a powerful tool to broadly and rapidly detect adventitious viruses for enhancing safety and product development of vaccines and other biologics.
While ongoing efforts have demonstrated feasibility for standardization and validation of this complex technology for adventitious virus detection, the industry could benefit from enhanced confidence in the use of NGS.

Solution

The FDA, along with GSK, MilliporeSigma, and the University of Delaware, will:

Compare NGS with currently used in vivo animal assay and in vitro cell culture and PCR assays to determine the applications of NGS as alternative assays
Develop a well-qualified reference virus database (RVDB II) that will facilitate specific detection of viruses for accurate interpretation of NGS data for adventitious virus detection.

Outputs/Deliverables

NGS study results supported replacement of in vivo animal assays and supplementing or replacing the in vitro cell culture assays.
Some limitation in NGS virus detection were identified for further optimization of the technology for sensitive virus detection for routine applications for adventitious virus detection, especially in a complex matrix.
Automated script was developed for updating the Reference Virus Database.
User friendly website features were implemented
Annotation pipeline was developed

Impacts

Reduce the use of animals for adventitious agent testing

Streamline and standardize bioinformatic analysis pipelines

Decrease cost and time required for adventitious virus testing, helping to facilitate more rapid product development

Assist regulatory agencies with decision-making and policy development regarding the use of NGS for replacing the in vivo animal assays and for replacing or supplementing the in vitro assays currently used for virus testing